Cormedix Inc (CRMD) - News Archive

DefenCath Receives Innovative Technology Designation: A Milestone for CorMedix Inc. and Dialysis Patient Care CorMedix Inc., a biopharmaceutical company dedicated to the development and commercialization of life-saving...

In the fast-paced world of biopharmaceuticals, the stakes are high, and the scrutiny is relentless. Recently, CorMedix Inc. (NASDAQ: CRMD) found itself in the spotlight as Kirby McInerney LLP announced an investigation...

CorMedix Inc. Joins Nasdaq Biotechnology Index Amid Positive Policy Changes for Hemodialysis Patients BERKELEY HEIGHTS, N.J. Dec. 19, 2024 In an exciting development for both stakeholders and the biotechnology sector, C...

On November 26, 2024, CorMedix Inc. a biopharmaceutical company focusing on therapeutic solutions for life-threatening diseases, issued a statement in support of recent policy updates released by the Centers for Medicar...

CorMedix Announces New Commercial Agreement with Mid-Sized Dialysis Operator CorMedix Inc. a biopharmaceutical company focused on developing and commercializing therapeutic products for cardiovascular and renal patients...

An Epoch of Hope in Renal Therapeutics: CorMedix Inc. Announces a Landmark Commercial AccordIn the illustrious annals of biomedical advancement, a significant chapter has recently been inscribed by the venerable CorMedi...

In a significant advancement for the field of biopharmaceuticals, CorMedix Inc. (Nasdaq: CRMD), a prominent player dedicated to the development of therapeutic solutions for severe and life-threatening health conditions,...

Introducing DefenCath: A Revolutionary Solution for Outpatient Dialysis and Inpatient UseCorMedix Inc., a prominent biopharmaceutical company, has recently made groundbreaking announcements regarding the availability of...

BERKELEY HEIGHTS, N.J. June 6, 2024 In a substantial stride for healthcare innovation, biopharmaceutical company CorMedix Inc. (Nasdaq: CRMD) has announced major advancements for their flagship product, DefenCath. This...

CorMedix Inc., a leading biopharmaceutical company specializing in the development of therapeutic products for critical diseases, has recently announced a significant commercial agreement with a top-tier midsized dialys...

CorMedix Inc., an industry-leading biopharmaceutical company committed to delivering innovative solutions for the treatment of life-threatening ailments, recently declared that their specialty product, DefenCath (Taurol...

article:Berkeley Heights, N.J. - CorMedix Inc. (Nasdaq: CRMD), a leading biopharmaceutical company focused on developing innovative therapeutic products for life-threatening diseases and conditions, has recently announc...

In an exciting development, CorMedix Inc., a renowned biopharmaceutical company dedicated to combating life-threatening diseases and conditions, has recently unveiled significant updates concerning its business operatio...

CorMedix Inc. Sets the Stage for Life-Saving Breakthrough with Commercial and Operational Updates Berkeley Heights, N.J., Jan. 08, 2024 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company dedicated to developing...

CorMedix Inc. Partners with The Leapfrog Group to Champion Patient Safety and Infection PreventionCorMedix Inc., a leading biopharmaceutical company specializing in infectious disease treatments, has recently announced...